Celsion announces continuing positive data from its phase 2 DIGNITY study in breast cancer
Celsion announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in recurrent chest wall breast cancer. The trial is designed to enroll up to 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. July 06, 2015